Browsing by Subject "gastroesophageal junction cancer"

Now showing items 1-2 of 2

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen, Selin Akturk; Ergun, Yakup; Erol, Cihan; Arikan, Rukiye; Er, Muhammed Muhiddin; Atci, Muhammed Mustafa; Topcu, Atakan; Ucar, Gokhan; Akagunduz, Baran; Aykan, Musa Baris; Ozen, Mirac; Baytemur, Naziyet Kose (ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO, 2022)

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no ...
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Basoglu, Tugba; Sakin, Abdullah; Erol, Cihan; Ozden, Ercan; cabuk, Devrim; Cilbir, Ebru; Tataroglu ozyukseler, Deniz; Ayhan, Murat; Sendur, Mehmet Ali; Dogan, Mutlu; Oksuzoglu, Berna; Eryilmaz, Melek Karakurt (TAYLOR & FRANCIS LTD, )

Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare ...